Techalt's SRO To Increase Presence in Collegiate Athletics Market

2008-08-20 23:44:04 -

- Techalt, Inc. (Pink Sheets:TCLT) ("Techalt" or "Company") reports Stanley Johnston, inventor of Stan's Rodeo Ointment ("SRO") and Stan's Blister Rub ("SBR"), has implemented an aggressive marketing campaign at colleges and university athletic programs. Mr. Johnston has commenced direct contact with key athletic personnel and plans to reach over 2,500 universities, colleges and junior colleges.

Stanley Johnston elaborated, "With

the success we had with the Major League Baseball league, National Basketball Association, National Hockey League, National Football League and in the 2008 Olympics, it is time to expose the collegiate programs to the benefits of using SRO and SBR. With only a 5% penetration into this market, SRO would obtain an opportunity to experience between a 30-55% increase in sales."

SRO, used by a wide variety of athletes and other consumers, is currently sold by prescription. Techalt is in discussions to obtain sufficient financing to take SRO Over-The-Counter. Upon FDA approval for Over-The-Counter Sales, the professional athletic, amateur athletic and the general consumer non-prescription markets will have the opportunity to conveniently benefit from this product.

Dr. Paul Sethi, an orthopedic surgeon from The ONS Sports and Shoulder Service in Greenwich, CT, who has worked with the Lakers, Kings, Avengers, Angels and Dodgers, asserted, "As a sports medicine surgeon in a community setting I have seen the problems and dysfunction that blisters and skin breakdown can cause. I have used Stan's Rodeo rub for numerous patients including throwing athletes, football players, track and field athletes, and recently in professional musicians. I have observed uniform success with pain reduction and rapid return to performance without recurrent blistering. I have no hesitation in recommending this product for the appropriate use, and it is a staple in my sports medicine practice."

About Stan's Rodeo Ointment ("SRO"):

SRO sports cream is designed to accelerate the healing time for abrasions, lacerations, blisters and other open wounds to the skin, while diminishing the pain. Developed by Stanley Johnston, former head athletic trainer for the Los Angeles Dodgers. Techalt also acquired the rights to develop Stan's Blister Rub ("SBR"), strengthens the skin after it has healed to reduce the likelihood of the reoccurrence of blisters to the applied area. Patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office. The Company anticipates that a patent will be issued sometime in 2008.

About Techalt:

Techalt is a public holding company dedicated to pursuing acquisition, licensing and financing opportunities with start-up and mid-stage companies. Techalt focuses on companies with innovative or alternative technologies, particularly in the software, communications, environmental and health and wellness sectors.

Media and Investor Relations: www.EquityDigest.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("the Exchange Act"), as such, may involve risks and uncertainties. Forward-looking statements are based upon certain assumptions and describe future plans, strategies and expectations, are generally identifiable by the use of words as "believe," "expect," "intend," "anticipate," "project," or other similar expressions. Forward-looking statements relate to, among other things, future performance, and perceived opportunities in the market and statements regarding the Company's mission and vision. The Company's actual results, performance and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements. Additional factors could materially affect these forward-looking statements and/or predictions include, among other things: (1) managing acquisitions and expansion of operations; (2) the ability of the Company to obtaining necessary financing to fund its business plan, including the financing needs for FDA approval of SRO, (3) the Company's ability to obtain FDA approval of SRO for OTC sales; (4) the Company's ability to manage existing debt; (5) completing the investigation, acquisition and integration of new business opportunities; (6) complying with federal, state and local government and international regulations; and (7) other factors over which we have little or no control.

Techalt, Inc., Seattle
Joseph J. Malone, 786-375-0556
Information@EquityDigest.com